Table 3.
General and SLE-specific laboratory feature trends across vaccinations.
| Laboratory Tests | Reference Range | Before Vaccination | After Dose 1 | After Dose 2 | After Vaccination | After Booster Dose |
|---|---|---|---|---|---|---|
| Timing with respect to each timepoint (days) | NA | 13 (6–20) | 17 (4–29) | NA | 7 (2–15) | |
| Laboratory test results | ||||||
| Haemoglobin (g/dL): median (IQR) | F: 12–16 M: 14–18 |
14.2 (13.3–15.1) |
13.7 (13.2–14.5) |
13.8 (13.4–14.6) ^ |
13.9 (12.9–14.4) § |
14.6 (12.2–14.9) |
| WBC/microlitre: median (IQR) | 4800–10,800 | 5100 (4400–6200) |
5350 (4175–5925) |
4450 (3593–5470) |
5145 (4150–7325) |
3690 (3300–5270) |
| Neutrophils (%): median (IQR) | 40–75 | 54 (51–60) | 61 (51–66) | 51 (47–64) | 60 (56–66) | 51 (50–54) |
| Lymphocytes (%): median (IQR) | 20–50 | 30 (28–34) | 27 (25–33) | 29 (23–37) | 22 (20–30) | 36 (33–37) |
| Monocytes (%): median (IQR) | 2–15 | 10 (7–10) | 9 (9–11) | 10 (7–10) | 10 (7–10) | 10 (10–10) |
| Eosinophils (%): median (IQR) | 1–6 | 3 (1–3) | 2 (2–3) * | 3 (1–5) * | 3 (1–5) | 2 (2–3) |
| Basophils (%): median (IQR) | 0–2 | 1 (0–1) | 0 (0–1) | 1 (0–1) | 1 (0–1) | 0 (0–1) |
| Platelets × 106/microlitre: median (IQR) | 130–400 | 237 (202–260) |
204 (139–222) |
195 (179–200) |
219 (190–258) |
229 (223–254) |
| Positive ADNA: n (%) | Negative | 5 (45) | ND | ND | 6 (60) | ND |
| Complement C3 (g/L): median (IQR) | 0.90–1.80 | 1.04 (0.95–1.09) |
ND | ND | 1.02 (0.89–1.07) |
ND |
| Complement C4 (g/L): median (IQR) | 0.10–0.40 | 0.18 (0.14–0.20) |
ND | ND | 0.23 (0.15–0.29) |
ND |
*: p < 0.05 compared to the pre-vaccination status; ^: p < 0.05 compared to the status after Dose 1; §: p < 0.05 compared to the status after Dose 2 by ranked sign test.